Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF
Inhibitors

KING OF PRUSSIA, Pa., Aug. 2 /PRNewswire/ -- Cytokine
PharmaSciences, Inc. (CPSI) today revealed that recent experiments
with its small-molecule MIF inhibitors showed oral efficacy in
animal models. Based on these results, the Company announced that
it is advancing one of these compounds into preclinical
development.

Macrophage Migration Inhibitory Factor, or MIF, is linked to
many conditions, including arthritis, asthma, cancer, sepsis,
inflammatory bowel disease and various infections and autoimmune
disorders. Neutralization of MIF biological activity has been shown
to have a protective effect against these diseases. CPSI has an
extensive patent portfolio focused on MIF, covering various methods
for neutralization, including small molecules. These compounds were
recently shown to be effective in animal models of multiple
sclerosis (MS) and arthritis when administered orally.

The MS animal experiments were conducted in the laboratories of
Dr. Abhay Satoskar and Dr. Caroline C. Whitacre, both of Ohio State
University in Columbus, OH. Dr. Satoskar stated: "The therapeutic
efficacy of these compounds was impressive with no outward signs of
toxicity. These findings indicate that small-molecule MIF
inhibitors are viable drug candidates for treating other autoimmune
and inflammatory diseases in which MIF has been identified as a
pathogenic factor." Dr. Whitacre adds: "The inhibitors were
especially effective in treating disease that had already started,
which is traditionally the most difficult hurdle for a new therapy.
We are very encouraged by these results."

The arthritis experiments were conducted under the guidance of
Drs. Thais M. Sielecki and Vidal F. de la Cruz of Cytokine
PharmaSciences, Inc. Dr. Sielecki observed: "We are encouraged to
have a small molecule MIF inhibitor that is orally active. MIF is
an important target in many diseases and an oral treatment is a
definite advantage." Dr. Sielecki will present the MS and arthritis
results at the annual American Chemical Society conference on
August 02, 20072, 2007, in Boston, MA.

Cytokine PharmaSciences is a biopharmaceutical company located
in King of Prussia (near Philadelphia), Pennsylvania. The company
licenses technologies from academia and other sources, develops
products from those technologies and outlicenses the products to
third parties for marketing. For more information, visit to
http://www.cytokinepharmasciences.com
.